Cyclooxygenase expressions and response to radiation therapy in uterine cervix cancer

Yong-Tark Jeon1, Sang-Soo Soo2, Jae Weon Kim1, Nob-Hyun Park1, Soon-Beom Kang1, Hyo-Pyo Lee1, Yong-Sang Song1
Department of Obstetrics and Gynecology, Cancer Research Institute, College of Medicine, Seoul National University, Seoul, Center for Uterine Cancer1, National Cancer Center, Ilsan, Korea

INTRODUCTION

Cervical cancer is one of the most common female cancers worldwide and is also the most common cancer of female genital tract in Korea.1 Although there have been a decreased incidence and increased early detection of cervical cancer mainly due to the well-organized cytology-based screening programs especially in developed countries,2 locally advanced cervical cancer comprises a significant proportion of the total patients with cervical cancer, particularly in developing countries.3 Radiation therapy has been a main treatment modality for locally advanced cervical cancer.

Various factors have been introduced as prognostic factors for cervical cancer including clinical stage, nodal involvement, tumor size, depth of stromal invasion, adenocarcinoma histology, microvessel density, tumor hypoxia, lymph-vascular space invasion, hemoglobin level, and interstitial tumor pressure.4-7 Recently, it has been reported that cyclooxygenase (COX)-2 expression in carcinoma of the cervix correlates with lymph node involvement in patients with stage IB disease treated with radical hysterectomy, and with diminished survival in patients treated with radiation therapy.8,9 Now, high expression of COX-2 in cervical cancer has been under massive investigation on a role as a prognostic indicator.

COX is a rate-limiting enzyme in producing eicosanoids and has two isoforms, COX-1 and COX-2. COX-1 is
constitutively expressed in various normal cells and is involved in the maintenance of physiologic conditions. On the other hand, COX-2 is induced during inflammation and by various mitogens, such as, growth factors and cytokines.\textsuperscript{10} It has been proposed that COX-2 may regulate cell proliferation, mitosis, cell adhesion, apoptosis, immune surveillance and/or angiogenesis during carcinogenesis.\textsuperscript{11-16} Expression of COX-2 is associated with metastasis and poor prognosis in several malignancies.\textsuperscript{8,17-19} Furthermore several studies show that COX-2 expression may be associated with resistance to radiation and chemotherapeutic agents.\textsuperscript{9,20,21} In addition, recent report indicate that COX-1 up-regulation modulates the expression of factors that may act in an autocrine/paracrine manner to enhance and sustain tumorigenesis in neoplastic cervical epithelial cells.\textsuperscript{22}

Although COX inhibitors are not used in cancer patients at present, it will be possible that non-steroidal anti-inflammatory drugs (NSAIDs) may be used routinely as a simple, cheap, and safe radiosensitizer, if the evidences for the relation of COX and radiation were sufficiently accumulated. Therefore the study to clarify the relationship of COX and radioresistance of cervix cancer is an interesting and valuable subject in the field of gynecologic oncology.

**MATERIALS AND METHODS**

1. Patients

Patients with cervical cancer treated by primary radiation therapy were selected from the tumor registry of Department of Therapeutic Radiology, Seoul National University Hospital from 1992 to 1997. Poor response to radiation was defined as follows; disease progression during radiation or no tumor regression after a month of radiation. Good response to radiation was that complete tumor regression during radiotherapy. For evaluation, weekly gynecologic examination was done during radiation therapy.

Among the stage IIA or higher staged uterine cervical cancer patients who had been treated with radical radiation therapy, 17 patients showed poor response to radiation. Of these patients, six patients, whose biopsy specimens were not available, were excluded, and remaining 11 patients (poor responder) were enrolled in this study. All patients in this group had histology of squamous cell carcinoma. For comparison, good response group were selected. Eleven patients (good responder) similar to poor responder in terms of stage and histology were selected.

The patients in poor response group were treated as follows; seven patients were treated with radiation therapy alone, and four patients were previously treated with neoadjuvant chemotherapy but revealed progressive disease. In all cases, 50.4 Gy was given to the whole pelvis, but seven patients could not receive brachytherapy. Poor geometry for brachytherapy due to no tumor shrinkage was the reason. Two patients were boosted with external beam radiotherapy with cone-downed fields.

All patients in good response group were treated with radiation therapy alone. In all cases, 50.4 Gy was given to the whole pelvis, followed by one or two course of low-dose-rate brachytherapy with a total dose of 83-85 Gy to point A. If the patient had parametrial involvement, 6-10 Gy boost were given to the involved parametrium. Patient characteristics are summarized in Table 1.

2. Immunohistochemical staining of COX-1, 2

Immunohistochemical staining was performed by the ABC method using formalin-fixed, paraffin-embedded tissue sections as described previously.\textsuperscript{23} Cervix cancer tissues were reacted with anti-COX-2 primary antibody (Transduction Lab., Lexington KY, USA) and with anti-COX-1 antibody (Santa Cruz Biotechnology, CA, USA) separately.

<table>
<thead>
<tr>
<th>Table 1. Patient characteristics</th>
</tr>
</thead>
<tbody>
<tr>
<td>Good responder</td>
</tr>
<tr>
<td>Age (yr)</td>
</tr>
<tr>
<td>Stage</td>
</tr>
<tr>
<td>Ila</td>
</tr>
<tr>
<td>IIB</td>
</tr>
<tr>
<td>Ila</td>
</tr>
<tr>
<td>IIB</td>
</tr>
<tr>
<td>IVa</td>
</tr>
</tbody>
</table>
All slides were incubated with biotinylated linker antibody (DAKO A/S, Copenhagen, Denmark) and finally with avidin/biotinylated horseradish peroxidase solution. The samples were exposed to diaminobenzidine and counterstained with Mayer's hematoxylin, and mounted in Permount (Fisher Scientific, Fair Lawn, USA). The percentage of cells expressing COX-2 and COX-1 was estimated by dividing the number of positively stained cells by the total number of cells per high-power field. Tumor sections were classified as positive staining if percentage of immunostained tumor cells was higher than median value (30% in COX-1 and 10% in COX-2).

3. Western blot and clonogenic assay

Cell lines derived from human cervical tumors were used: HeLa, HT3, and C33A. Cells were obtained from American Type Culture Collection (Manassas, VA, USA) and were maintained as exponentially growing monolayers in Dulbecco's Modified Eagle Medium (DMEM) and RPMI 1640 (Sigma-Aldrich, St. Louis, MO, USA) containing 5% fetal bovine serum.

To determine COX levels in cervical cancer cell lines, cells were trypsinized, washed with phosphate-buffered saline (PBS), and the cell pellet was resuspended in 50 µl lysis buffer [1×Protease Inhibitor Cocktail (Roche Molecular Biochemicals, Indianapolis, IN, USA) in RIPA buffer (150 mM NaCl, 0.1% SDS, 50 mM Tris, pH 8.0, 1% Triton X-100)]. The suspension was placed on ice for 20 min and then centrifuged at 4°C for 20 min at 13,000 rpm, after which the supernatant was recovered. Protein concentrations were determined using the protein assay kit bicinchoninic acid (Pierce Biotechnology Inc., Rockford, IL, USA). Twenty µg of cell lysate protein were separated on 12% SDS-PAGE polyacrylamide gel with Laemmli buffer and the proteins then transferred to an Immobilon-P membrane (Millipore Corp., Bedford, MA, USA). After the transfer, the membrane was blocked with 5% nonfat milk in TBS-T (0.05% Tween 20, 10 mM Tris-HCl pH 8.0, 150 mM NaCl) for 1 hr and then washed twice with TBS-T for 10 min each time. PGHS-1 and 2, IgG fraction of a mouse anti-COX-1 and -2 antibody (Oxford Biomedical Research Inc., Oxford, MI, USA), were then added at a 1:500 dilution for 2 hrs. The membrane was washed 3 times with TBS-T for 10 min each. The secondary goat anti-mouse IgG alkaline phosphatase conjugate (Bio-Rad Lab., Hercules, CA, USA) was added at a 1:1,000 dilution for 2 hrs. The membrane was washed 3 times in TBS-T and detection was performed using an enhanced chemiluminescence (ECL) system (Amersham Bioscience, Arlington Heights, IL, USA).

The sensitivity of the cervix cancer cells to radiation was measured using a clonogenic assay. Cultured cells were exposed to SC-236 (10 µM or 50 µM) for 3 days. Then the cells were irradiated with graded doses (0, 2, 4, or 8 Gy) of γ-rays using a 137Cs source (3.7 Gy/min). Colony-forming ability of cells was assayed by re-plating them in specified numbers into 60 mm dishes in drug-free medium. After 14 days of incubation, the cells were stained with 0.5% crystal violet in absolute ethanol, and colonies with more than 50 cells were counted. Radiation survival curves were plotted after normalizing for the cytotoxicity induced by SC-236 alone. Clonogenic survival curves were constructed from three independent experiments by fitting the average survival levels using least-squares regression by the linear-quadratic model.

**RESULTS**

COX-1 and COX-2 expressions were higher in poor responders than good responders as shown in Table 2. The difference of COX-1 expression between two groups had marginal statistical significance (p=0.099, Fisher's exact test).

<table>
<thead>
<tr>
<th>Table 2. Results of the immunohistochemical staining</th>
</tr>
</thead>
<tbody>
<tr>
<td>COX-1 expression</td>
</tr>
<tr>
<td>Positive</td>
</tr>
<tr>
<td>3</td>
</tr>
<tr>
<td>7</td>
</tr>
<tr>
<td>0.099</td>
</tr>
</tbody>
</table>
test). However, COX-2 expression was significantly higher in poor responders (p=0.034, Fisher’s exact test).

As shown in Fig. 1, C33A cell line did not express COX-1 and COX-2. On the contrary, HeLa and HT-3 cell lines had both COX-1 and COX-2 expression. In the clonogenic assay, as shown in Fig. 2, survival fraction of HeLa and HT-3 cell lines, which have COX-1 and COX-2 activity, was significantly higher than C33A cell line (p<0.001).

DISCUSSION

Our results suggest that the expression of COX in cervical cancer might be deeply associated with the effect of radiation therapy. In the immunohistochemical staining study, patients who were resistant to radiation therapy had high COX expression. In additional experiment using clonogenic assay, COX expressing cell lines, HeLa and HT-3, were more resistant to ionizing radiation than C33A which has no COX activity. These results support the association of COX expression with radioresistance in cervix cancer.

As described in Introduction section, it has been proposed that COX-2 may play an important role in carcinogenesis, metastasis, poor prognosis, and resistance to radiation. Recent clinical study on patients with cervical cancer who underwent radiation therapy also revealed the relationship of COX-2 expression with poor prognosis.5,24 Recently, Sales et al. showed that overexpression of COX-1 in HeLa cells up-regulates expression of COX-2 and prostaglandin E synthase concomitant with increased prostaglandin E2 production.22 In addition, Narko et al. showed that COX-1 overexpression in endothelial cells implanted in mice was associated with enhanced tumorigenicity.25 Taken together, COX-1 might be important in cell survival and/or proliferation as COX-2 did.

Numbers of studies showed that COX-2 is increased in premalignant and malignant tissues of human. These studies cover gastrointestinal tract, liver, pancreas, head and neck, lung, breast, urinary bladder, uterine cervix, endometrium, and skin.15,26-35 Although the exact functional role(s) of increased COX-2 in tumor tissues have not been fully elucidated yet, there have been several proposed mechanisms on the role of tumor-derived prostanooids; angiogenesis,36 cell proliferation,37 resistance to apoptosis,38 and metastatic potential and/or invasiveness of a tumor.39 On the basis of these works, lots of studies were initiated to prevent cancer and to increase an efficacy of conventional cancer therapy with the use of COX inhibitor in general population and cancer patients. Regarding radiotherapy with COX inhibitor, Liao et al. reported encouraging results in non-small cell lung cancer patients using celecoxib.40 Currently, the Radiation Therapy Oncology Group (www.rtog.org) is conducting clinical trials in cervix cancer, lung cancer and brain tumors, using inhibitors of COX-2 in combination with chemotherapy and radiation therapy.
Although cervix cancer is a radiocurable disease, there have been substantial concerns over frequent treatment failure of radiotherapy in locally advanced disease. Recent large randomized clinical trials have shown survival benefit of the concurrent use of cisplatin-based chemotherapy with radiation in patients with locally advanced disease or high-risk settings. In terms of additional chemotherapeutic agent during radiotherapy can cause more serious morbidity and increased cost, there has been incessant need for cheap and safe radiosensitizer. COX inhibitors are promising candidates for these purposes. However exact action mechanism(s) of these drugs to cancer cells is largely unknown at present and precise role(s) of COX, moreover, is only partially understood. We think that this study, although need further investigation, suggested small clue for verifying the enzymes’ role in radiosensitivity modulation and for developing appropriate radiosensitizer of cervix cancer.

REFERENCES


자궁경부암에서 싸이클로로옥시데나제의 발현과 방사선치료 효과와의 관계

서울대학교 의과대학 산부인과학학교실, 국립암센터
진용택1, 서상수2, 김재원1, 박노현1, 강수범1, 이효표1, 송용상1

목적: 자궁경부암에서 싸이클로로옥시데나제의 발현과 방사선치료에 대한 반응성 사이의 관련을 알아보고자 하였다.

연구방법: 자궁경부암으로 방사선치료를 받은 환자들 중 방사선치료에 대한 반응이 좋지 않았던 11명의 환자와 방사선치료에 대한 반응이 좋았던 11명의 환자를 선택하였고, 보관된 암 조직에 대하여 싸이클로로옥시데나제-1,2의 발현을 면역조직화학법을 통하여 알아보았다. 또한, 세 가지 자궁경부암 세포주(HeLa, HT-3, C33A)에 대하여 Western blot을 통해 싸이클로로옥시데나제-1,2의 발현을 확인하고 싸이클로로옥시데나제의 발현 차이에 따라 방사선 감수성의 변화가 있는지 clonogenic assay를 통하여 알아보았다.

결과: 면역조직화학법 결과 싸이클로로옥시데나제-1의 발현은 방사선치료에 대한 반응이 좋지 않았던 군에서 많이 발현되었으나 통계적 유의성은 높지 않았다(p=0.099, Fisher's exact test). 싸이클로로옥시데나제-2의 발현은 방사선치료에 대한 반응이 좋지 않았던 군에서 유의하게 많이 발현되었다(p=0.034, Fisher's exact test). Western blot에서 HeLa와 HT-3 세포주는 싸이클로로옥시데나제-1,2가 모두 발현되는 것을 알 수 있었고, C33A 세포주는 싸이클로로옥시데나제의-1,2의 발현이 없었다. Clonogenic assay에서는 HeLa와 HT-3 세포주의 생존 분율이 C33A 세포주보다 유의하게 높았다(p<0.001).

결론: 본 연구를 통하여 자궁경부암에서 싸이클로로옥시데나제의 발현은 방사선치료 자체에 대한 저항성과 깊은 관련이 있을 가능성을 확인하였다.

중심단어: 자궁경부암, 싸이클로로옥시데나제, 방사선치료